Association of high-density lipoprotein cholesterol with improvement of endothelial dysfunction recovery in renovascular disease.

Introduction: This study was aimed to assess the ratio of total cholesterol (TC) to high-density density lipoprotein cholesterol (HDLC) and plasma nitrate levels in patients with ischemic nephropathy receiving statins and niacin extended release (NER).

Materials And Methods: Kidney disease patients with a history of at least 5 year of diabetes mellitus or 10 year of hypertension were screened by renal artery Doppler ultrasonography. Participants were randomly assigned into two groups to receive atorvastatin, 20 mg/d, with and without NER, 500 mg/d, for 16 weeks.

Hypophosphatemic effect of niacin extended release in ischemic kidney disease.

Ischemic nephropathy is an emerging cause of end stage renal disease, associated with many co-morbidities especially cardiovascular disease risk and derangement in calcium-phosphorus homeostasis resulting in hyperphosphatemia, influencing bones, a characteristic of advancing chronic kidney disease. The management of elevated serum phosphorus has been a challenge in this patient population with compromised kidney performance, as available phosphorus lowering agents possess many undesirable hazardous secondary effects and/or are very expensive. While niacin in different formulation is known to not only correct dyslipidemia but also reduce phosphorus level, but its clinical use restricted owing to side effects.

Etiology and outcome of acute renal failure in pregnancy.

Objective: To determine the etiology and outcome of Acute Renal Failure (ARF) in pregnancy.

Study Design: A case series.

Place And Duration Of Study: Nephrology Department of the Jinnah Postgraduate Medical Centre, Karachi, from August 2007 to July 2008.